Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc.

Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc.

By late June, Cara Therapeutics, Inc. (NASDAQ: CARA) stock had soared more than 175% year to date. Within a couple of weeks, however, many of those gains had been lost. Cara shares crashed after the biotech reported disappointing results from a phase 2 study of experimental pain drug CR845.

While the stock has climbed back somewhat, Cara is still well below the lofty levels of earlier in the summer. Can the comeback continue? I think so. Here's why the best is probably yet to come for Cara Therapeutics. 

Image source: Getty Images.

Continue reading

Source: Fool.com